Harrow vs Puma Biotechnology
Harrow reported revenue of $272 million in fiscal 2025, 1.2 times Puma Biotechnology's $228 million in fiscal 2025. Harrow's revenue grew 36.4% in its latest year, and Puma Biotechnology's fell 0.9%. Harrow had an operating margin of 11.2%, against 16.3% at Puma Biotechnology. Free cash flow was $43 million at Harrow and $42 million at Puma Biotechnology.
Side by side
| Harrow | Puma Biotechnology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $272M | $228M |
| Revenue growth | 36.4% | −0.9% |
| Revenue growth a year, last 5 years | 41.0% | 0.3% |
| Gross margin | 75.0% | 74.5% |
| Operating margin | 11.2% | 16.3% |
| Net margin | −1.9% | 13.6% |
| Free cash flow | $43M | $42M |
| Free cash flow margin | 15.8% | 18.3% |
| Return on capital | — | 48.2% |
| Net debt to EBITDA | 5.5x | −1.4x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.1% | 3.2% |
| Last close | $30.12 | $7.77 |
| P/E at the last close | — | 16.9× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 6 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
HarrowPuma Biotechnology
Operating margin
Percent of revenue
HarrowPuma Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
HarrowPuma Biotechnology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Harrow and Puma Biotechnology pages.